There is a comforting story circulating through cannabis brand teams right now: Federal rescheduling is finally happening. Schedule III reform will normalize banking, ease interstate commerce constraints, expand medical research, and reduce the regulatory friction that has held the category back. Once federal clarity arrives, the brand-building work can begin.
The story is only partially true. Federal rescheduling is happening. The December 2025 Trump executive order, the April 2026 DOJ final order, the DEA’s registration portal, and the scheduled June through July administrative hearing all confirm it. But the brand-building work began some time ago. It happened during 2024. It happened during 2025. It is happening every quarter that an AI engine routes a “best cannabis brand” or “best cannabis dispensary” prompt to a brand other than yours.
The concentration of AI citations
5W PR’s Cannabis AI Visibility Index 2026, released this month, makes the point quantitatively. The Index measured AI citation share across ChatGPT, Claude, Perplexity, and Google’s AI Overviews using more than fifty consumer-intent prompts in the first quarter of 2026. The findings: Three multistate operators (MSOs) — Curaleaf, Trulieve, and Green Thumb Industries — captured an estimated 17.5 percent of all cannabis-category AI citations. The gap between those three and the rest of the MSO field is meaningful and widening. Cookies leads branded consumer products with a citation gap to second place wider than the gap between the top two MSOs. Charlotte’s Web has held the number-one CBD position for five years, and that sector’s moat is widening, not narrowing.
The mechanism is concentration. AI engines do not produce evenly distributed citations across long brand lists. They concentrate citations on the small number of brands that have produced credentialed, structured, state-specific content depth. Each quarter, the cited brands accrue more citations because their citation history reinforces their authority to the next iteration of the AI model. Consequently, the uncited brands accrue less. The compounding runs in both directions and it does not pause for federal reform.
The Schedule III illusion
Federal Schedule III reform will benefit every cannabis brand operating in the medical space today — and, potentially, in the adult-use space soon. Banking access, federal tax relief through Internal Revenue Code Section 280E reform, expanded medical research authorization, and reduced compliance burdens are real wins. None of those wins erase the citation moat that Curaleaf, Trulieve, Green Thumb, Cookies, Charlotte’s Web, Leafly, and Weedmaps have built. None of those wins automatically surface a brand AI engines have not been citing already.
Changing the prompts, not the players
What Schedule III does is change the questions consumers ask AI engines. It changes “Is cannabis legal in my state?” to “What does Schedule III mean for medical cannabis access in my state?” It changes “best cannabis dispensary near me” to “best Schedule III medical cannabis provider near me.” It changes the prompt language brands need to be cited inside.
The brands that produced Schedule III content in 2026’s first quarter captured citation share for those new prompts. The brands that wait for the Schedule III rulemaking process to conclude before publishing will arrive after the citation surface has already concentrated.
Capitalizing on the AI ‘hedge’ window
There is also a category-wide pattern Schedule III will not change. Approximately 28 percent of cannabis prompts produce AI engine refusals, hedges, or prominent disclaimers — the highest rate of any consumer category 5W measured. Schedule III rescheduling will reduce that rate, but it will not eliminate it. State-by-state variation will persist. Medical-versus-adult-use distinctions will persist. Drug-interaction concerns will persist. The hedge rate may move from 28 percent to 18 percent or 15 percent, and that movement will create a new wave of opportunity for the brands that publish credentialed content into the new hedge surface and a new wave of irrelevance for the brands that do not.
The cannabis brand that waited through Schedule I is not going to get a do-over from Schedule III. The compounding does not pause. The window does not widen.
The compounding cost of waiting
What works from here is what worked from 2024: state-specific legal and qualifying-condition content, credentialed-author medical applications coverage, structured product-by-product education, regulatory-event-driven publication cadence, and consistent presence on the aggregators AI engines treat as neutral. The brands doing that work today are running ahead of Schedule III. The brands waiting for Schedule III to begin the work are running behind it.
An expert in crisis communications, Ronn Torossian is founder and chairman of 5W PR. After founding the firm in 2003, he built it into one of the largest independently owned public relations firms in the United States, with a team of more than 275 professionals serving clients across corporate, consumer, technology, crisis, public affairs, and digital marketing. Torossian has counseled blue-chip companies, public-company boards, founders, and public figures through ransomware incidents, data breaches, regulatory investigations, high-stakes litigation, activist investor campaigns, product recalls, and reputational crises. He has lectured on crisis PR at Harvard Business School. A regular guest on CNN and CNBC, he is also a contributing columnist for Forbes and the New York Observer and is the author of For Immediate Release: Shape Minds, Build Brands, and Deliver Results With Game-Changing Public Relations, now in its second edition. Torossian is a recipient of the Stevie American Business Awards Entrepreneur of the Year and the American Business Awards PR Executive of the Year and was named to Business Insider’s Top Crisis Communications Professionals.
